Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

A Study of Pembrolizumab and Cryoablation in People With Breast Cancer

NCT: NCT06246968 · RECRUITING

NCT IDNCT06246968
StatusRECRUITING
Start Date2024-01-29
Completion2027-01-29

Brief Summary

Participants will have a confirmed diagnosis of metastatic breast cancer and will receive pembrolizumab in combination with cryoablation OR pembrolizumab alone. Participants will be randomly assigned.

Frequently Asked Questions

What is A Study of Pembrolizumab and Cryoablation in People With Breast Cancer?

A Study of Pembrolizumab and Cryoablation in People With Breast Cancer is a clinical trial registered under NCT06246968. Current status: RECRUITING.

What is the status of NCT06246968?

The current status of NCT06246968 (A Study of Pembrolizumab and Cryoablation in People With Breast Cancer) is: RECRUITING.

When did A Study of Pembrolizumab and Cryoablation in People With Breast Cancer start?

A Study of Pembrolizumab and Cryoablation in People With Breast Cancer started on 2024-01-29.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑